• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      DUODOPA Enables Your Patients to Continue Their Gold Standard Treatment

      For levodopa-responsive patients with complex/advanced Parkinson’s


      Motor

      In a study, DUODOPA provided predictability of ‘ON’ time and ‘OFF’ time2

      In a 54-week safety study, patients with severe motor fluctuations on DUODOPA had a significant increase in 'ON' time without troublesome dyskinesia and a significant decrease in 'OFF' time compared with baseline (both p<0.001), which was sustained throughout the study.2

      Patient video: Richard's story

      "I’d arranged a trip… I was able to go with no interruptions from the drug… there were no tremors, no freezing, I could walk properly."
      Richard, 2017. Duodopa patient

      Non-Motor

      In a study, DUODOPA had a greater effect on total non-motor symptom score than apomorphine3*

      In a 6-month study comparing the effects of DUODOPA and apomorphine, increase from baseline in non-motor symptom scale (NMSS) score was:3

      • DUODOPA +0.83
      • Apomorphine +0.53
      • Both treatments had similar efficacy for motor scores and HRQoL

      Significant results:3

      • Duodopa: Sleep/fatigue (p=0.017);* Gastrointestinal (p=0.004);*  Urinary (p=0.0001);*  Sexual function (p=0.001)*
      • Apomorphine: Mood/apathy (p=0.03)*

      In a study, benefits in non-motor symptoms were sustained over a period of two years with DUODOPA4

      In a 24-month registry study evaluating safety and efficacy of Duodopa, significant and sustained improvements in motor fluctuations and associated non-motor symptoms were observed (p<0.001)†4

      Particularly in:4

      • Sleep/fatigue (p<0.001) 
      • Mood/cognition (p=0.004)
      • Gastrointestinal symptoms (p<0.001)

      Improvement measured by reduction from baseline in the mean non-motor symptoms scale (NMSS) scores.

      Patient video: Steve's story

      "Because there were 2 years when I couldn’t do anything, I’m overcompensating, by doing things 7 days a week."
      Steve, 2017. Duodopa patient

      Convenience

      Dosing is reliable with the smooth delivery of DUODOPA1

      Reliable:

      Duodopa offers a reliable solution around the problem of delayed gastric emptying1

      Smooth:

      The consistent delivery of DUODOPA smooths out any peaks or troughs in plasma concentration1

      Adjustable:

      Dosing can be individually optimised to suit the patient, over a 16-hour period1


      Dyskinesia

      In a study, DUODOPA provided significant and sustained reductions in dyskinesia5

      In a 12-week study, advanced PD patients were randomised to receive either OMT (n=33) or DUODOPA (n=28).5

      Patients who received DUODOPA had sustained and significant improvements in UDysRS total scores through Week 12 compared to OMT (p<0.001).5

      At Week 12, compared to OMT, patients treated with DUODOPA experienced5:

      • 3.27 hours more ‘ON’ time without troublesome dyskinesia (3.15 hours with DUODOPA vs -0.12 hours with OMT; p=0.0001)

      • 2.35 hours less ‘OFF’ time (-2.17 hours with DUODOPA vs 0.18 hours with OMT; p=0.0002)

      Patient video: Grace's story

      "We used to have a wheelchair in the house and Brian used to push me around in the wheelchair for the times I couldn’t walk. But I always had a pusher… "
      Grace, 2017. Duodopa patient

      Safety & Tolerability

      DUODOPA has a well-understood safety profile2

      An open-label study shows DUODOPA offers a well-understood adverse event profile2

      • For the majority of patients adverse events are mild (19%) or moderate (44%) and transient2
      • Low withdrawal rate (8%) due to adverse events, most commonly due to complication of insertion of device2

      For more detailed safety information, please refer to the Summary of Product Characteristics (SmPC).


      I want to receive more information about DUODOPA


      References

      1. Nyholm D, et al. AAPS J 2013;15:316–23.
      2. Fernandez HH, et al. Mov Disord 2015;30:500–9.
      3. Martinez-Martin P, et al. Mov Dis 2015;30:510–6.
      4. Antonini A, et al. Parkinsonism Relat Disord 2017;45:13–20.
      5. Alvarez EF, et al. Presented at the MDS Virtual Congress, 12–16 September 2020:867.
       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

       UK-DUOD-210079. Date of preparation: May 2021.